

# Tim A Kanters

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7242971/publications.pdf>

Version: 2024-02-01

30  
papers

557  
citations

623574

14  
h-index

677027

22  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1003  
citing authors

#	ARTICLE	IF	CITATIONS
1	Update of the Dutch manual for costing studies in health care. PLoS ONE, 2017, 12, e0187477.	1.1	151
2	Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. Journal of Inherited Metabolic Disease, 2016, 39, 253-260.	1.7	43
3	Burden of illness of Pompe disease in patients only receiving supportive care. Journal of Inherited Metabolic Disease, 2011, 34, 1045-1052.	1.7	29
4	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. Orphanet Journal of Rare Diseases, 2014, 9, 75.	1.2	26
5	Orphan drugs expenditure in the Netherlands in the period 2006-2012. Orphanet Journal of Rare Diseases, 2014, 9, 154.	1.2	23
6	Potential cost savings owing to the route of administration of oncology drugs. Anti-Cancer Drugs, 2018, 29, 791-801.	0.7	23
7	Cost comparison of two implantable cardiac monitors in two different settings: Reveal XT in a catheterization laboratory vs. Reveal LINQ in a procedure room. Europace, 2016, 18, 919-924.	0.7	22
8	Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. Frontiers in Pharmacology, 2017, 8, 322.	1.6	21
9	Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Orphanet Journal of Rare Diseases, 2013, 8, 124.	1.2	19
10	Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria. British Journal of Dermatology, 2018, 179, 702-708.	1.4	19
11	The impact of informal care for patients with Pompe disease: An application of the CarerQol instrument. Molecular Genetics and Metabolism, 2013, 110, 281-286.	0.5	18
12	A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands. BMJ Open, 2018, 8, e019864.	0.8	18
13	Care-related Quality of Life of informal caregivers of the elderly after a hip fracture. Journal of Patient-Reported Outcomes, 2018, 2, 23.	0.9	16
14	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet Journal of Rare Diseases, 2017, 12, 179.	1.2	15
15	Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 557-559.	0.7	13
16	Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic. Pharmacoeconomics, 2022, 40, 77-90.	1.7	13
17	Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study. Orphanet Journal of Rare Diseases, 2018, 13, 59.	1.2	11
18	Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab. Breast, 2020, 52, 71-77.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision. <i>Pharmacoeconomics</i> , 2021, 39, 383-397.	1.7	11
20	A conceptual disease model for adult Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 112.	1.2	10
21	Burden of Providing Informal Care for Patients with Atrial Fibrillation. <i>Value in Health</i> , 2021, 24, 236-243.	0.1	9
22	International differences in patient access to ultra-orphan drugs. <i>Health Policy and Technology</i> , 2018, 7, 57-64.	1.3	7
23	Multi-Criteria Decision Analysis for Reimbursing Orphan Drugs: A Dutch Demonstration Study Using the Analytic Hierarchy Process Method. <i>Value in Health</i> , 2014, 17, A541-A542.	0.1	6
24	Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE). <i>Frontiers in Neurology</i> , 2020, 11, 3.	1.1	6
25	In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era. <i>Pharmacoeconomics</i> , 2022, 40, 7-11.	1.7	6
26	A new prevention paradox: The trade-off between reducing incentives for risk selection and increasing the incentives for prevention for health insurers. <i>Social Science and Medicine</i> , 2013, 76, 150-158.	1.8	3
27	Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy. <i>Value in Health</i> , 2021, 24, 1470-1475.	0.1	3
28	Cost Effectiveness of Splenic Artery Embolization versus Splenectomy after Trauma in the Netherlands. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 392-398.e4.	0.2	3
29	Quality of Life and Participation in the Daily Life (Activities) of Adults with Pompe Disease Receiving Enzyme Replacement Therapy: 10 Years of International Follow-Up. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, S63-S63.	1.1	1
30	Assessing Costs Using the Treatment Inventory Cost in Psychiatric Patients (TIC-P), TIC-P Mini and TIC-P Midi. <i>Journal of Mental Health Policy and Economics</i> , 2019, 22, 15-24.	0.6	1